Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

Wake Forest University (WFU)

Status and phase: Withdrawn; Early Phase 1

Conditions: Central Centrifugal Cicatricial Alopecia

Treatments: Drug: Subject's already prescribed drug; Drug: Calcipotriol

Study type: Interventional

Funder types: Other

Identifiers

NCT05416320

IRB00076702

Details and patient eligibility

About

The purpose of this pilot study is to determine if calcipotriol shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). This study aims to evaluate calcipotriol due to the possible anti-inflammatory effects that may affect the hair growth cycle.

Full description

Calcipotriol, a vitamin D analog, has been topically used to treat alopecia areata, a form of non-scarring autoimmune alopecia in several studies. It is possible that Vitamin D plays a role in sustaining the hair follicle's immune privilege through anti-inflammatory effects such as controlling Interferon gamma (IFN-γ) production. A recent study showed a significant decrease of vitamin D in Black patients with Central Centrifugal Cicatricial Alopecia (CCCA)"

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women who are eighteen years of age or older
• biopsy-proven and/or clinical diagnosis of CCCA Stage II-IV
• must be on stable treatment without changes for at least 3 months
• Subjects will be recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology.

Exclusion criteria

• Males

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

Calcipotriol Group

Experimental group

Description:

Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.

Treatment:

Drug: Calcipotriol

Control Group

Sham Comparator group

Description:

Subjects will continue to use their primary physician prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.

Treatment:

Drug: Subject's already prescribed drug